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As a leukemia physician with an interest in epigenetic therapy of
cancer, I found ‘Histone deacetylases’ not only timely but very
informative. The term epigenetic alterations refers to biochemical
modifications of the chromatin, at the DNA, protein and RNA
levels, that have an impact, among several other functions, on gene
transcription regulation. Interest in two of these modifications,
DNA methylation and alterations of histone code, stands not only
from their fundamental molecular implications, but also from a
therapeutic perspective. These two modifications are the target of
anticancer drugs with either hypomethylating or histone deacety-
lase (HDAC) inhibitory activity. Indeed, three drugs, 5-azacitidine,
5-aza-2
0
-deoxycitine and suberoylanilide hydroxamic acid (SAHA),
have been approved for clinical use in the United States. The first
two drugs are hypomethylating agents with activity in myelodys-
plastic syndromes and other leukaemias. The third drug, a potent
HDAC inhibitor, was approved for cutaneous lymphoma, and it
also has clinical activity in other disorders.
HDACs are a very complex group of proteins. They are divided
into three families: Class 1 (HDAC 1, -2, -3 and -8); Class 2 (HDAC
4, -5, -6, -7, -9, -10 and -11); and Class 3 (SIRT 1–7). The function
of these groups of proteins is now starting to be understood. It
is also clearly emerging that HDACs can regulate acetylation of
other nonhistone proteins, adding significant complexity to this
field. Furthermore, to date, the anticancer mechanisms of action of
HDAC inhibitors are unknown. It is also not known whether
induction of histone acetylation, that is well documented to occur
in vivo after administration of HDAC inhibitors, is a key mediator
of their anticancer activity. Therefore, the importance and need of
a comprehensive book source for investigators and individuals
with interest in this area.
This text is divided into four main chapters focusing on each
HDAC class family and a final chapter on HDAC inhibitors.
Subsequently, each chapter is divided into subchapters addressing
specific HDACs or topics of interest. Most of these subchapters
are of interest, and although there is some degree of redundancy,
common in this type of multiauthor books and mainly in
the introductory remarks, a wealth of data, both historic and
current, is presented. Most chapters are succinct and to the point,
and this makes for easy reading. More importantly, all chapters
come with a very extensive and relevant set of references that, in
many cases, are as useful as the text itself. In particular, chapter
three, which relates to class 3 HDACs, is very useful as this is a
relatively newer area of knowledge and broad potential clinical
interest. The figures and tables are small in number and of limited
value, specifically those tables/figures of protein/gene sequence
alignments.
Unfortunately, the weakest area of the book review is the one
that relates to the translational applications, in particular against
cancer, of the information provided here. For instance, there is
little in terms of potential Sirtuin inhibitors. Furthermore, only
two subchapters focus on HDAC inhibitors. These chapters are
not sufficiently updated (probably because of the delays intrinsic
to this type of publication). The book would have significantly
benefited from a more systematic review of the clinical activity and
studies with this class of drugs.
Despite this limitation, I strongly recommend this text,
especially for those (like myself) who want and need a condensed,
well-referenced guide to the area of HDACs. In that sense, this
book more than fulfils its objective.
G Garcia-Manero
University of Texas MD Anderson Cancer Center, Houston,
Texas, USA
British Journal of Cancer (2007) 96, 1153
& 2007 Cancer Research UK All rights reserved 0007– 0920/07 $30.00
www.bjcancer.com